Physician profile
Korathu Thomas
NPI 1376565390
$1,539.07
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $59.65 · 2021: $91.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $1,121.12 | 2019 | |
| Astellas Pharma US INC | $95.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $84.75 | 2019 | |
| Janssen Biotech, INC. | $79.99 | 2021 | |
| Merck Sharp & Dohme LLC | $35.53 | 2019 | |
| Seagen INC. | $32.96 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.29 | 2020 | |
| Amgen INC. | $20.90 | 2019 | |
| Genentech USA, INC. | $19.66 | 2020 | |
| Lilly USA, LLC | $12.95 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Korathu Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.